LOGIN  |  REGISTER
Recursion
C4 Therapeutics

Health Catalyst to Participate in Upcoming Investor Conference

August 31, 2023 | Last Trade: US$5.61 0.07 -1.23

SALT LAKE CITY, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Bryan Hunt, Chief Financial Officer, and Adam Brown, Senior Vice President of Investor Relations and FP&A, will participate in the Wells Fargo Healthcare Conference, being held in Boston, including a fireside chat presentation on Thursday, September 7, 2023 at 3:45pm EST.

About Health Catalyst

Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations committed to being the catalyst for massive, measurable, data-informed healthcare improvement. Its customers leverage the cloud-based data platform—powered by data from more than 100 million patient records and encompassing trillions of facts—as well as its analytics software and professional services expertise to make data-informed decisions and realize measurable clinical, financial, and operational improvements. Health Catalyst envisions a future in which all healthcare decisions are data informed.

Health Catalyst Investor Relations Contact:

Adam Brown
Senior Vice President, Investor Relations and FP&A
+1 (855)-309-6800
This email address is being protected from spambots. You need JavaScript enabled to view it.

Health Catalyst Media Contact:

Tarah Neujahr Bryan
Chief Marketing Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.

Viking Therapeutics

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page